3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis

Molecular Cancer Therapeutics

Volumn 10, Issue 11, 2011, Pages 2146-2156

  Subramaniam, Dharmalingam ^a,b   Nicholes, Nathan D ^c   Dhar, Animesh ^a,b   Umar, Shahid ^c   Awasthi, Vibhudutta ^d   Welch, Danny R ^a,b   Jensen, Roy A ^a,b   Anant, Shrikant ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 BIS(2,4 DIFLUOROBENZYLIDENE) 4 PIPERIDONE; ANGIOGENESIS INHIBITOR; CASPASE 3; CASPASE 7; CD31 ANTIGEN; CYCLIN A1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; GAMMA SECRETASE; INTERLEUKIN 8; JAGGED1; MESSENGER RNA; NICASTRIN; NOTCH1 RECEPTOR; PIPERIDONE DERIVATIVE; PRESENILIN 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG SCREENING; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLIDENE COMPOUNDS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PIPERIDONES; RECEPTORS, NOTCH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81055148335     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0399     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
3. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
4. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty?Oncologist 2008;13:562-76. (Pubitemid 351872873)
5. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997;33:S18-22.
6. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900. (Pubitemid 33051148)
7. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1996;1317:95-100.
8. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98. (Pubitemid 36361976)
9. Subramaniam D, RamalingamS, Linehan DC, Dieckgraefe BK, Postier RG, Houchen CW, et al. RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. PLoS One 2011;6:e16958.
10. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 2010;343:489-99.
11. Shehzad A, Khan S, Shehzad O, Lee YS. Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today (Barc) 2010;46:523-32.
12. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it?Mol Nutr Food Res 2008;52:1010-30.
13. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008;75:787-809.
14. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004;12:3871-83. (Pubitemid 38798249)
15. Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, Sun A, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 2005;16:263-75. (Pubitemid 40283941)
16. Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 2008;68:1962-9. (Pubitemid 351416583)
17. Miele L. Notch signaling. Clin Cancer Res 2006;12:1074-9. (Pubitemid 43342494)
18. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med 2006;6:905-18. (Pubitemid 44883940)
19. Miele L, Miao H, Nickoloff BJ. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 2006;6:313-23. (Pubitemid 43961866)
20. Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A 2008;105:18913-8.
21. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV, et al. Inhibition of g-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009;136:1741-9e6.
22. Landegren U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods 1984;67:379-88. (Pubitemid 14163018)
23. Ponnurangam S, Mondalek FG, Govind J, Subramaniam D, Houchen CW, Anant S, et al. Urine and serum analysis of consumed curcuminoids using an IkappaB-luciferase surrogate marker assay. In Vivo 2010;24:861-4.
24. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003;15:725-31. (Pubitemid 37492933)
25. Blanchard H, Donepudi M, Tschopp M, Kodandapani L, Wu JC, Grutter MG. Caspase-8 specificity probed at subsite S(4): crystal structure of the caspase-8-Z-DEVD-cho complex. J Mol Biol 2000;302:9-16.
26. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007;6:24.
27. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-62. (Pubitemid 29418754)
28. Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther 2007;6:1569-75. (Pubitemid 351590328)
29. Grau R, Iniguez MA, Fresno M. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase- 2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator- activated receptor-gamma-independent mechanism. Cancer Res 2004;64:5162-71. (Pubitemid 39006534)
30. Pavlakovic H, Havers W, Schweigerer L. Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumour therapy. Angiogenesis 2001;4:259-62. (Pubitemid 34832370)
31. Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, et al. Translation regulatory factor RBM3 is a protooncogene that prevents mitotic catastrophe. Oncogene 2008;27:4544-56.
32. Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res 2009;69:2757-65.
33. Li H, Wolfe MS, Selkoe DJ. Toward structural elucidation of the g-secretase complex. Structure 2009;17:326-34.
34. Wolfe MS. g-secretase in biology and medicine. Semin Cell Dev Biol 2009;20:219-24.
35. Gong P, Vetrivel KS, Nguyen PD, Meckler X, Cheng H, Kounnas MZ, et al. Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of g-secretase activity toward amyloid precursor protein and other substrates. J Biol Chem 2010;285:38042-52.
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
37. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Downregulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase- 9 in pancreatic cancer cells. Cancer Res 2006;66:2778-84.
38. Bachmeier BE, Killian P, Pfeffer U, Nerlich AG. Novel aspects for the application of Curcumin in chemoprevention of various cancers. Front Biosci (Schol Ed) 2010;2:697-717.
39. Surh YJ, Chun KS. Cancer chemopreventive effects of curcumin. Adv Exp Med Biol 2007;595:149-72.
40. Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 2002;9:1287-93. (Pubitemid 36097698)
41. Cascinu S, Scartozzi M, Carbonari G, Pierantoni C, Verdecchia L, Mariani C, et al. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol 2007;30:526-30. (Pubitemid 47537955)
42. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999;5:3711-21.
43. Le X, Shi Q, Wang B, Xiong Q, Qian C, Peng Z, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2000;20:935-46.
44. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:1996-2003. (Pubitemid 34408443)
45. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
46. Benedit R, Roca C, Sorenson I, Adams S, Gossler A, Fruttiger M, et al. The Notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009;137:1124-35.